Neurocrine Biosciences, Inc. v. Teva Pharmaceuticals, Inc. et al
| Neurocrine Biosciences, Inc. |
| Teva Pharmaceuticals, Inc., Teva Pharmaceuticals Development, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. |
| 1:2022cv00092 |
| January 21, 2022 |
| US District Court for the District of Delaware |
| Maryellen Noreika |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on March 21, 2022. A more recent docket listing may be available from PACER.
| Document Text |
|---|
SO ORDERED re (19 in 1:21-cv-01148-MN, 15 in 1:21-cv-01067-MN, 21 in 1:21-cv-01043-MN, 14 in 1:21-cv-01464-MN, 26 in 1:21-cv-01118-MN, 12 in 1:21-cv-01408-MN, 15 in 1:21-cv-01042-MN, 21 in 1:21-cv-01553-MN, 8 in 1:22-cv-00092-MN) Stipulation to Extend Time to submit proposed scheduling order - IT IS HEREBY ORDERED that the deadline to submit the proposal scheduling order is extended through and including 3/24/2022. ORDERED by Judge Maryellen Noreika on 3/21/2022. (dlw)
|
| Filing 8 STIPULATION Seeking to Extend the Deadline by which a Proposed Scheduling Order is Due, by Neurocrine Biosciences, Inc.. (Balick, Steven) |
|
SO ORDERED re (16 in 1:21-cv-01553-MN, 14 in 1:21-cv-01067-MN, 18 in 1:21-cv-01148-MN, 25 in 1:21-cv-01118-MN, 13 in 1:21-cv-01464-MN, 7 in 1:22-cv-00092-MN, 14 in 1:21-cv-01042-MN, 20 in 1:21-cv-01043-MN, 11 in 1:21-cv-01408-MN) Stipulation to Extend Time to submit a proposed scheduling order through and including 3/18/2022. ORDERED by Judge Maryellen Noreika on 3/10/2022. (dlw)
|
| Filing 7 STIPULATION Seeking to Extend the Deadline by which a Proposed Scheduling Order is Due, by Neurocrine Biosciences, Inc.. (Balick, Steven) |
|
Filing 6
ORAL ORDER - IT IS HEREBY ORDERED that, within thirty (30) days from the date of this Order, the parties shall confer regarding proposed dates in the scheduling order and shall submit a proposed order, which is also consistent with the following guidance. The parties shall provide final contentions (i.e., final infringement and invalidity contentions, as well as final non-infringement and validity contentions) around the time that fact discovery closes (i.e., several weeks prior to or after the deadline to complete fact discovery) and at least three weeks before Plaintiff serves its opening claim construction brief. Final contentions shall include a party's contentions under its proposed construction(s), as well as under the opposing construction(s) (if such an alternative contention exists). As such, the parties are encouraged to exchange proposed claim terms and proposed constructions early in the case but in no event later than necessary to allow the parties to include alternative contentions in their final contentions. The joint claim construction chart shall be due one week after the parties have completed their exchange of final contentions, and the joint claim construction brief must be filed at least three weeks before the claim construction hearing. The parties shall leave at least three weeks between the claim construction hearing and the opening of expert discovery. The parties are to use the Court's form scheduling order, which is posted at http://www.ded.uscourts.gov (see Chambers, Judge Noreika, Forms), and the parties must include a proposal for the length and timing of trial. If there are disputes or issues that the Court needs to address in the proposed scheduling order, the parties shall direct the Court to the paragraph numbers in which those appear in a cover letter to the Court. ORDERED by Judge Maryellen Noreika on 2/9/2022. (dlw)
|
| Case Assigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. (rjb) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Neurocrine Biosciences, Inc.. (twk) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,026,931; 11,026,939; 11,040,029. (twk) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: December 13, 2021. Date of Expiration of the 931 Patent: August 14, 2039. Date of Expiration of the 939 Patent: September 18, 2038. Date of Expiration of the 029 Patent: October 10, 2037. Hatch-Waxman Regulatory Exclusivity Deadline: October 11, 2024. (twk) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) |
| Filing 1 COMPLAINT FOR PATENT INFRINGEMENT filed against Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals Development, Inc., Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3786973.) - filed by Neurocrine Biosciences, Inc.. (Attachments: #1 Exhibit A, #2 Civil Cover Sheet)(twk) |
| No Summons Issued. (twk) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
